Page 37 - Read Online

Cheson. J Cancer Metastasis Treat 2022;8:8 https://dx.doi.org/10.20517/2394-4722.2021.153 Page 5 of 6

Study Group. Blood 2005;106:3725-32. DOI PubMed
9. Herold M, Haas A, Srock S, et al; East German Study Group Hematology and Oncology Study. Rituximab added to first-line
mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with
advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-92. DOI
PubMed
10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse
large-B-cell lymphoma. N Engl J Med 2002;346:235-42. DOI PubMed
11. Czuczman MS, Leonard JP, Johnson JL, et al. FLIPI score is applicable and predictive of response to upfront immunotherapy in
CALGB 50402: phase II trial of extended induction galiximab ([G] anti-CD80 monoclonal antibody) plus rituximab [R]. Blood
2008;112:1003. DOI
12. Grant BW, Jung SH, Johnson JL, et al. A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated
follicular lymphoma: CALGB 50701. Cancer 2013;119:3797-804. DOI PubMed PMC
13. Leonard JP, Jung SH, Johnson J, et al. Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with
recurrent follicular lymphoma: CALGB 50401 (Alliance). J Clin Oncol 2015;33:3635-40. DOI PubMed PMC
14. Martin P, Jung SH, Pitcher B, et al. A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's
lymphoma (NHL): CALGB 50803 (Alliance). Ann Oncol 2017;28:2806-12. DOI PubMed PMC
15. Fowler NH, Davis RE, Rawal S, et al. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-
label, phase 2 trial. Lancet Oncol 2014;15:1311-8. DOI PubMed PMC
16. Leonard JP, Trneny M, Izutsu K, et al; AUGMENT Trial Investigators. AUGMENT: a Phase III Study of Lenalidomide plus
Rituximab versus Placebo plus Rituximab in relapsed or refractory indolent lymphoma. J Clin Oncol 2019;37:1188-99. DOI PubMed
PMC
17. Morschhauser F, Fowler NH, Feugier P, et al; RELEVANCE Trial Investigators. Rituximab plus Lenalidomide in advanced untreated
follicular lymphoma. N Engl J Med 2018;379:934-47. DOI PubMed
18. Morschhauser F, Tilly H, Chaidos A, et al. Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label,
single-arm, multicentre, phase 2 trial. Lancet Oncol 2020;21:1433-42. DOI PubMed PMC
19. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med
2013;369:32-42. DOI PubMed PMC
20. O’brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p
deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol 2016;17:1409-18. DOI PubMed
21. Burger JA, Tedeschi A, Barr PM, et al; RESONATE-2 Investigators. Ibrutinib as initial therapy for patients with chronic lymphocytic
leukemia. N Engl J Med 2015;373:2425-37. DOI PubMed PMC
22. Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med
2016;374:323-32. DOI PubMed PMC
23. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for
treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet 2020;395:1278-91.
DOI
24. Hillmen P, Brown JR, Eichhorst BF, et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic
leukemia/small lymphocytic lymphoma. Future Oncol 2020;16:517-23. DOI PubMed
25. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet
2021;397:892-901. DOI PubMed
26. Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and
efficacy results. Blood 2015;126:739-45. DOI PubMed PMC
27. Tam CS, Opat S, D’Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström
macroglobulinemia: the ASPEN study. Blood 2020;136:2038-50. DOI PubMed PMC
28. Wang M, Rule S, Zinzani PL, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm,
multicentre, phase 2 trial. Lancet 2018;391:659-67. DOI PubMed PMC
29. Owen RG, Mccarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm,
multicentre, phase 2 study. Lancet Haematol 2020;7:e112-21. DOI PubMed
30. Wang M, Shah NN, Alencar AJ, et al. LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously
treated mantle cell lymphoma, Waldenström’s macroglobulinemia, and other non-Hodgkin lymphomas: results from the phase 1/2
BRUIN study. Blood 2020;136:8-10. DOI
31. Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med
2019;380:2225-36. DOI PubMed
32. Jain N, Keating M, Thompson P, et al. Ibrutinib and Venetoclax for first-line treatment of CLL. N Engl J Med 2019;380:2095-103.
DOI PubMed
33. Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med
2014;370:1008-18. DOI PubMed PMC
34. Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib
followed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol 2019;37:1391-402. DOI
PubMed
35. Dreyling M, Santoro A, Mollica L, et al. Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent